Eli Lilly & Co. (NYSE: LLY) Q2 2020 earnings call dated July 30, 2020 https://www.youtube.com/watch?v=d4-cSFo067A Presentation: Operator Ladies and gentlemen, thank you
Eli Lilly and Company
-(LLY)
LLY Earnings: All you need to know about Eli Lilly Q2 2020 earnings results
Eli Lilly and Company (NYSE: LLY) reported second quarter 2020 earnings results today. Revenues declined 2% year-over-year to $5.4 billion. Reported net
Eli Lilly (LLY) appears to be on a strong footing with COVID-19 drug development efforts
Eli Lilly & Co.’s (NYSE: LLY) shares have gained 29% since the beginning of the year and 16% over the past three
Eli Lilly & Co (NYSE: LLY) Q1 2020 Earnings Call Transcript
Eli Lilly & Co (LLY) Q1 2020 earnings call dated Apr. 23, 2020 Corporate Participants: Kevin Hern -- Vice President, Investor Relations David A.
Eli Lilly (LLY) reports Q1 2020 earnings results
Pharmaceutical company Eli Lilly (NYSE: LLY) reported first quarter 2020 revenue of $5.86 billion, up 15% year-over-year. Amid COVID-19 pandemic, the company
Eli Lilly & Co (NYSE: LLY) Q4 2019 Earnings Call Transcript
Eli Lilly & Co (NYSE: LLY) Q4 2019 Earnings Conference Call January 30, 2020 Corporate Participants: Kevin Hern -- Vice President of Investor Relations David
Eli Lilly beats Q3 earnings expectations; revenues miss estimates
Eli Lilly and Company (NYSE: LLY) surpassed earnings expectations for the third quarter of 2019 but revenues came in shy of estimates.
Eli Lilly Q2 profit beats estimates, lifts FY19 forecast
Eli Lilly and Company (NYSE: LLY) swung to a profit in the second quarter of 2019 from a loss last year, helped
What’s in store for top pharma stocks this year
The stocks of leading pharmaceutical firms shifted to growth mode this year after winding up 2018 on a low note, in line
Eli Lilly’s stock down after Q1 revenues miss forecasts
Eli Lilly and Company (NYSE: LLY) surpassed analysts’ expectations on earnings for the first quarter of 2019 while revenues fell short of
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of
Amarin shares jump 14% on rumors over Novartis interest
Shares of Amarin Corp (AMRN) gained up to 14% during the regular trading hours on Friday as rumors of an acquisition once
Eli Lilly Q4 profit misses estimates, cuts 2019 outlook
Eli Lilly and Company (LLY) swung to a profit in the fourth quarter from a loss last year, helped by lower asset
Earnings Preview: New drugs to propel Eli Lilly forward
Eli Lilly and Company (LLY) is scheduled to report earnings results for the fourth quarter of 2018 on February 6, 2019, before
Earnings preview: Merck to ride the wave of expanding oncology portfolio in Q4
The general market sentiment on Merck & Co. (MRK) is quite bullish ahead of the drug maker’s fourth-quarter earnings report. Analysts predict
Eli Lilly’s oncology push suffers a blow after sarcoma drug fails study
The ambitious cancer therapy program of Eli Lilly and Company (LLY) suffered a setback Friday after a formulation developed by the drug
In a massive deal, Eli Lilly acquires Loxo Oncology
Eli Lilly and Company (LLY) on Monday announced that it would acquire a small biopharmaceutical startup that develops cancer treatment, Loxo Oncology
Eli Lilly to collaborate with AC Immune for the treatment of Alzheimer’s disease
Eli Lilly (NYSE: LLY) partners with Switzerland-based AC Immune (Nasdaq: ACIU) to research and develop the potential treatment for Alzheimer's disease and
Eli Lilly tops market estimates; revises guidance
Eli Lilly and Company (LLY) reported better-than-expected results on revenue and earnings for the third quarter of 2018 and revised its guidance
Companies reporting earnings this week: Nov 5-9
A slew of major companies are reporting earnings this week. Generic drugmaker Mylan Inc. (MYL) will announce third-quarter earnings on Monday after